CYGNUS Business Consulting & Research, Sep 2011, Pages: 304
opportunities in overseas market
- Major Therapeutic R&D Pipeline
- Emerging trends in drug development
- Vital details on 32 major players in Indian Market (listed and Unlisted both in BSE & NSE)
- New
GBI Research, April 2012, Pages: 98
Market to 2018, ClinicalTrial Market, Argentina ($m), 2008–2018
Table 9: Contract Research Organization Market to 2018, ClinicalTrial Market, India, ($m), 2008–2018
Table 10: Contract Research Organization
GlobalData, Nov 2011, Pages: 18
, musculoskeletal, emergency care, radiology, pediatrics, urology and obstetrics/gynecology areas. The company is a joint venture between Wipro Limited and General Electric Company and it is a part of GE Healthcare
Espicom Business Intelligence Ltd, April 2011, Pages: 118
Ophthalmology Drug Futures: Sight Preservation in Chronic Eye Diseases Ophthalmology Drug Futures: An expanding market with high unmet clinical need and huge commercial opportunity
A complete
Bioplan Associates Inc., Jan 2008, Pages: 766
over the past few years, with sales exceeding US$1.5 billion. As domestic demand for improved healthcare, and international opportunities for biologics increase, India will continue to expand its
Digital Vector, April 2007, Pages: 325
to conduct any discovery research or clinicaltrials. Till now this has been the focus of most Indianplayers.
ANALOGUE OR DISCOVERY RESEARCH
Companies modify an existing molecule or a new one that has
RNCOS E-Services Private Limited, Aug 2011, Pages: 145
Booming ClinicalTrials Market in IndiaIndia has billion plus population and a home for various life threatening diseases. These factors provide an opportunity for global medical practitioners
Credit Analysis & Research Limited, Dec 2011, Pages: 133
) Biosimilars and biopharmaceuticals opportunity
f) Clinical Research
6) Domestic demand and growth drivers
7) Industry characteristics of Indian Pharma
a) Low cost advantage and skilled manpower
b) Export
GlobalData, April 2012, Pages: 70
-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emergingplayers with potentially strong product portfolio and create effective counter-strategies to gain
MP Advisors, Jan 2011, Pages: 391
analysts have studied 200 clinical and regulatory upcoming events, changing dynamics in generic players on back of dozens of Para IV, new found love by large cap innovators in generics and emerging markets
Global Industry Analysts, Inc., July 2009, Pages: 558
Stages of ClinicalTrials II-23
Pharmaceutical Industry: Review of the Present Scenario II-25
Developing
Gyan Research and Analytics Pvt. Ltd., May 2012, Pages: 68
and diverse spectrum of Indianhealthcare, with emphasis on opportunities in the areas of hospital infrastructure, pharmaceuticals, medical equipment, diagnostic labs and emerging fields like healthcare tourism
GBI Research, Aug 2011, Pages: 87
and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely
GlobalData, Aug 2011, Pages: 65
information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinicaltrials, wherever applicable
Global Industry Analysts, Inc., Jan 2012, Pages: 69
ClinicalTrials 23
Opportunities in the Life Sciences Industry 24
Pharmaceutical Industry: A Haven for Mining Opportunities 24
Challenges Posed by the Regulatory Environment 25
LIMS in Clinical
TriMark Publications, Sep 2010, Pages: 308
Opportunities
Table 3.63: Indian IVD Market for Instruments and Reagents, 2004-2012
Table 3.64: Number of Automated Clinical Labs in India, 2004-2012
Table 3.65: Indian IVD Market
Table 3.66: Japanese
GlobalData, Sep 2011, Pages: 33
on clinicaltrials, wherever applicable.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team
CYGNUS Business Consulting & Research, Nov 2010, Pages: 243
, the Golden Quadrilateral has emerged as a golden opportunity for the healthcare industry in India. The government plans to invest Rs7.5 billion to develop health centres in partnership with Apollo Group
